Observational studyIn vivo (Athens, Greece)
Efficacy of Switching from Prior Nonsteroidal Anti-inflammatory Drugs to Transdermal Diclofenac in Cancer Pain Management.
Observational study in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimNonsteroidal anti-inflammatory drugs (NSAIDs) are recommended for mild cancer pain and can be combined with opioids for moderate-to-severe pain. The efficacy of switching from prior NSAIDs to transdermal diclofenac in patients with cancer has not been fully evaluated, however. PATIENTS AND
methodsWe conducted a retrospective observational study at the Cancer Institute Hospital, Ariake, Japan, from May 21, 2021, to May 20, 2023. Hospitalized of patients with cancer who were switched from prior NSAIDs to transdermal diclofenac were included. Patients were excluded if they never applied the patch, could not continue treatment for ≥7 days, or had dementia/delirium precluding pain assessment. The primary endpoint was change in numerical rating scale (NRS) score from baseline (Day 0) to Day 8. Statistical analyses were performed using the Wilcoxon signed-rank test, with
resultsA total of 72 patients were included. The median age was 67 years, and 46 were female. Prior NSAIDs included loxoprofen, flurbiprofen, naproxen, and celecoxib. Concomitant opioids were used in 55 patients. Mean NRS score decreased from 3.8 to 2.4 by Day 8 (
conclusionSwitching to transdermal diclofenac effectively reduced pain in patients with cancer and may serve as a useful alternative when oral or prior NSAID therapy is difficult to continue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.